FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

A

Agilent TechnologiesNYSE · Life Sciences Tools & Services · Health Care
Previous close
174.87
Change
−6.28 / −3.47%
FinDog View
Neutral
52-Week Range ?
108.35 – 182.99
P/E (TTM) ?
34.8
Sector median 29.5
Forward P/E ?
25.0
Based on consensus earnings for the next 12 months
Market Cap
$49.3B
1M
+1.49%
S&P 500 −0.91% over same period
Volume / Avg Volume
2.8M / 2.0M
1.35× average
Latest earnings analysisFY2026 Q3Reported 2026-08-26

Agilent Q3 FY26: revenue up 8.1%, margins jump, guidance raised

Agilent's fiscal third quarter was its strongest of the year: revenue rose 8.1% to $1.878 billion, gross margin reached 55.5%, and non-GAAP EPS climbed 18% to $1.62. Management also raised full-year revenue and EPS guidance. Read the margin story carefully, though, because about 110 basis points of the operating-margin gain came from tariff refunds that future guidance excludes.

Read the full analysis →
Revenue$1.88BYoY +8.10%
EPS (non-GAAP)$1.62
Next-quarter revenue guidance$1.99B ±0.5%Below estimatesest. $2.03B
Next-day move+1.68%

Price History

Closing price · USD1M6M1Y5Y
100120140160180200EFY26 Q3 EarningsEFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 Earnings2025-102026-012026-052026-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 29.51M6M1Y5Y
20253035402026-042026-062026-082026-092026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-23
in 22 days · After hours
Consensus EPS
$1.76
Last quarter EPS $1.62
Avg. next-day move over the last 6 reports
±5.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 95 of its 5-year rangeExpensive
5-year range 24.9 – 34.9 · Median 30.1
Last 4 quarters: $380M in buybacks + $286M in dividends, 1.35% of market cap combined
P/E (TTM)
34.8
P/B
6.8
P/S
6.8
Dividend Yield
0.75%
Earnings Reaction
Over the last 6 reports, the stock moved ±5.2% on average on the first trading day after, rising 5 times
Most recent +1.68%
Guidance Credibility
Of the last 4 next-quarter revenue guides, 3 were met; actual results averaged 2.0% above guidance
Volatility & Correlation
1-year beta 0.89 · Correlation with S&P 500 0.35Tracks the market
Annualized volatility 33% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 1 · $0.10MNet selling $0.10M
  • 09-04Dolsten MikaelDirectorSell$0.10M634 shares · Avg price 151.38
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q31.88+8.1%55.5%0.440.360.441.28
FY2026 Q21.84+10.0%54.0%0.400.340.201.20
FY2026 Q11.80+7.0%52.6%0.350.310.181.07
FY2025 Q41.86+9.4%53.2%0.440.430.451.53
FY2025 Q31.74+10.1%51.1%0.360.340.261.18
FY2025 Q21.67+6.0%51.9%0.300.220.110.75
FY2025 Q11.68+1.4%53.5%0.380.320.331.11
FY2024 Q41.70+0.8%53.9%0.410.350.391.23
FY2024 Q31.58−5.6%54.2%0.330.280.360.97
FY2024 Q21.57−8.4%54.4%0.360.310.231.05
FY2024 Q11.66−5.6%54.8%0.380.350.401.18
FY2023 Q41.69−8.7%54.2%0.410.480.431.60

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView